Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) – Equities researchers at Wedbush issued their Q1 2023 EPS estimates for shares of Ascendis Pharma A/S in a research note issued on Thursday, March 3rd. Wedbush analyst L. Moussatos forecasts that the biotechnology company will post earnings per share of ($1.98) for the quarter. Wedbush has a […]
Credit Suisse AG lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 67.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,410 shares of the biotechnology company’s stock after selling 2,904 shares during the quarter. Credit Suisse AG’s […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) had its price target decreased by investment analysts at Wells Fargo & Company from $176.00 to $170.00 in a research report issued on Thursday, The Fly reports. Wells Fargo & Company‘s price objective would indicate a potential upside of 59.65% from the company’s current price. ASND has been […]
Geode Capital Management LLC boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 1.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,796 shares of the biotechnology company’s stock after purchasing an additional 519 shares during the quarter. Geode Capital […]
US Bancorp DE Has $146,000 Position in Ascendis Pharma A/S (NASDAQ:ASND) etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.